851785-70-1

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-(5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid is used as a potential pharmaceutical compound for its structural features commonly found in drugs and bioactive molecules. The specific biological activities and potential therapeutic applications of (S)-2-(5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid would need to be determined through further research and testing.

Upstream product

• 851784-80-0 2-(tert-butyl) 6-methyl 5,7-dichloro-3,4-dihydroisoquinoline-2,6(1Η)-dicarboxylate 
• 851784-76-4 tert-butyl 5,7-dichloro-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 851784-82-2 2-(tert-butoxycarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 
• 851785-21-2 methyl (2s)-2-amino-3-(3-(methylsulfonyl)phenyl)propionate hydrochloride 
• 1194550-63-4 C₄₆H₄₀Cl₂N₂O₅S 
• 1194550-56-5 5,7-dichloro-2-trityl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 

Downstream Products

• 1025967-78-5 (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid 

Relevant academic research and scientific papers

NOVEL PROCESS FOR THE PREPARATION OF LIFITEGRAST

The present invention relates to a novel process for the preparation of lifitegrast of Formula (I). The present invention further provides a novel process for the purification of lifitegrast of Formula (I).

PROCESSES FOR PREPARATION OF LIFITEGRAST AND INTERMEDIATES THEREOF

The present invention provides process for preparation of lifitegrast, amine salts of lifitegrast, process for preparation of amine salts of lifitegrast and their use in purification of lifitegrast, and also provided are process for preparation of amorphous lifitegrast and pharmaceutical compositions comprising lifitegrast prepared by the processes of the present invention.

MODULATORS OF CELLULAR ADHESION

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).